Kraj: Kanada
Język: angielski
Źródło: Health Canada
DEQUALINIUM CHLORIDE
DUCHESNAY INC
G01AC05
DEQUALINIUM
10MG
VAGINAL TABLET
DEQUALINIUM CHLORIDE 10MG
VAGINAL
15G/50G
Prescription
ANTIBIOTICS
Active ingredient group (AIG) number: 0107638003; AHFS:
APPROVED
2021-07-28
_Vablys (dequalinium chloride vaginal tablets) Product Monograph _ _Page 1 of 20_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr VABLYS TM Dequalinium chloride vaginal tablets Tablets, 10 mg, Vaginal Anti-infective and Antiseptic Agent Duchesnay Inc. 950 boul. Michèle-Bohec Blainville, Quebec Canada, J7C 5E2 Date of Initial Approval: September 1, 2021JUL 27, 2021 Submission Control No: 227886 Annotated Product Monograph - EN Pg. 1 _ _ _Vablys (dequalinium chloride vaginal tablets) Product Monograph _ _Page 2 of 20_ TABLE OF CONTENTS TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ................................................................. 4 1 INDICATION ................................................................................................................... 4 1.1 Pediatrics ............................................................................................................. 4 1.2 Geriatrics ............................................................................................................. 4 2 CONTRAINDICATIONS .................................................................................................. 4 3 DOSAGE AND ADMINISTRATION ................................................................................ 4 3.1 Dosing Considerations ......................................................................................... 4 3.2 Recommended Dose and Dosage Adjustment ..................................................... 5 3.3 Administration ...................................................................................................... 5 3.4 Missed Dose ........................................................................................................ 5 4 OVERDOSAGE ............................................................................................................... 6 5 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACK Przeczytaj cały dokument